VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 336 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2017. The put-call ratio across all filers is 1.53 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $2,851,000 | +87.1% | 137,217 | -0.7% | 0.29% | -1.4% |
| Q1 2017 | $1,524,000 | +379.2% | 138,132 | +530.7% | 0.30% | +360.9% |
| Q4 2016 | $318,000 | +925.8% | 21,901 | +1335.2% | 0.06% | +481.8% |
| Q2 2016 | $31,000 | -91.7% | 1,526 | -89.3% | 0.01% | -93.1% |
| Q1 2016 | $374,000 | -38.3% | 14,226 | +318.4% | 0.16% | -69.8% |
| Q3 2015 | $606,000 | – | 3,400 | – | 0.53% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,577,892 | $994,984,000 | 31.62% |
| Ruane, Cunniff & Goldfarb | 33,922,192 | $6,051,041,000 | 31.06% |
| LeVasseur Capital Partners LLC | 162,394 | $28,968,000 | 29.76% |
| FARLEY CAPITAL L.P. | 192,130 | $34,272,000 | 27.18% |
| Pershing Square Capital Management | 19,473,933 | $3,473,760,000 | 24.90% |
| Arrow Capital Management, LLC | 109,461 | $19,525,000 | 16.53% |
| Marble Arch Investments | 1,196,900 | $213,503,000 | 16.43% |
| Tesuji Partners | 1,368,040 | $244,414,000 | 15.82% |
| ValueAct Holdings | 14,994,261 | $2,674,676,000 | 15.55% |
| Hound Partners | 3,898,648 | $695,441,000 | 15.04% |